Since insulin resistance and hyperinsulinaemia are central to the pathogenesis of PCOS, it is natural to expect insulin sensitisers to be of benefit in the management of the condition (Pasquali and Gambineri, 2009). The gene discussed is INS; the disease is polycystic ovary syndrome.